Read by QxMD icon Read

long term effects of proton pump inhibitors

Nicole A Huijgen, Maria A J de Ridder, Katia M Verhamme, Gert R Dohle, Ann M Vanrolleghem, Miriam C J M Sturkenboom, Joop S E Laven, Régine P M Steegers-Theunissen
OBJECTIVE: To determine associations between proton-pump inhibitor (PPI) use and semen parameters in young men of couples who are planning pregnancy. DESIGN: Case-control study of a population-based registry. SETTING: Not applicable. PATIENT(S): General practitioner patients comprising 2,473 men from couples planning pregnancy with a recorded semen analysis: 241 with a low total motile sperm count (TMSC ≤1) and 714 with TMSC >1 as matched controls...
October 12, 2016: Fertility and Sterility
Timothy Nguyen, Roza Gavrilova, Marina Blazhko
Older adults frequently have multiple medical conditions and consequently receive multiple medications. Cardiovascular (CV) and gastrointestinal disorders are two conditions in seniors that often require both long-term antiplatelet therapy and medications for GI prophylaxis. Clopidogrel and pantoprazole are commonly used for these conditions; however, there are potential adverse consequences secondary to drug interactions. Both of these drugs are metabolized via the cytochrome P450 system, and there is a potential for drug interactions that may result in decreased effectiveness of clopidogrel and an increased risk of adverse CV outcomes...
2016: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
Brenda Hartman, Mary Donnelly-VanderLoo, Tiffany Watson, Colleen O'Connor, Janet Madill
The risk for impaired vitamin B12 status increases with age, as does the use of proton pump inhibitors (PPI). Long-term use of PPIs is associated with several nutritional deficiencies including B12. Currently, there are no recommendations for B12 screening among patients taking PPIs. Data were abstracted on B12 concentrations, B12-containing supplement use, medications, and select hematological values from a retrospective chart review of 658 adults, 391 with serum B12 concentrations, admitted to 6 different medical units at 2 regional hospitals in Southwestern Ontario between 2010 and 2012...
June 23, 2016: Applied Physiology, Nutrition, and Metabolism, Physiologie Appliquée, Nutrition et Métabolisme
Jarrett J Failing, Heidi D Finnes, Lisa A Kottschade, Jacob B Allred, Svetomir N Markovic
Ipilimumab can induce long-term survival in 20% of patients with metastatic melanoma. Concurrent chronic medications may impact the patient's immune system, possess antimelanoma properties, and potentially affect clinical outcomes. This retrospective study sought to describe the efficacy and toxicity effects of 12 classes of chronic medications in metastatic melanoma patients treated with ipilimumab. A total of 159 adults who received ipilimumab for metastatic melanoma at Mayo Clinic (Rochester, Minnesota, USA) from 1 March 2011 through 31 December 2014 were included...
September 3, 2016: Melanoma Research
Birgitte-Elise G Emken, Lars R Lundell, Lene Wallin, Helge E Myrvold, Cecilia Engström, Madeleine Montgomery, Anders R Malm, Tore Lind, Jan G Hatlebakk
OBJECTIVE: To compare the effect of anti-reflux surgery (ARS) versus proton pump inhibitor therapy on lower oesophageal sphincter (LOS) function and oesophageal acid exposure in patients with chronic gastro-oesophageal reflux disease (GORD) over a decade of follow-up. MATERIAL AND METHODS: In this randomised, prospective, multicentre study we compared LOS pressure profiles, as well as oesophageal exposure to acid, at baseline and at 1 and 10 years after randomisation to either open ARS (n = 137) or long-term treatment with omeprazole (OME) 20-60 mg daily (n = 108)...
September 3, 2016: Scandinavian Journal of Gastroenterology
S Sun, Z Cui, M Zhou, R Li, H Li, S Zhang, Y Ba, G Cheng
BACKGROUND AND PURPOSE: Proton pump inhibitors (PPIs) are commonly used as potent gastric acid secretion antagonists for gastro-esophageal disorders and their overall safety in patients with gastro-esophageal reflux disease (GERD) is considered to be good and they are well-tolerated. However, recent studies have suggested that PPIs may be a potential independent risk factor for cardiovascular adverse events. The aim of our meta-analysis was to examine the association between PPI monotherapy and cardiovascular events in patients with GERD...
August 30, 2016: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
Agnieszka Matuszewska, Beata Nowak, Marta Rzeszutko, Krzysztof Zduniak, Marta Szandruk, Diana Jędrzejuk, Marcin Landwójtowicz, Marek Bolanowski, Małgorzata Pieśniewska, Joanna Kwiatkowska, Adam Szeląg
BACKGROUND: Epidemiological studies suggest that long-term administration of proton pump inhibitors (PPIs) may decrease bone mineral density (BMD) and increase the risk of osteoporotic fractures. The aim of the study was to assess the influence of pantoprazole on bone metabolism in growing rats. METHODS: The experiment was carried out on twenty-four young male Wistar rats divided into two groups receiving either pantoprazole at the dose of 3mg/kg or vehicle for 12 weeks...
October 2016: Pharmacological Reports: PR
Evan W Colmenares, Ashley L Pappas
OBJECTIVE: The purpose of this article is to describe the relationship between proton pump inhibitors (PPIs) and symptoms of myopathy based on case reports. DATA SOURCES: A literature search was conducted in PubMed (1946 to June 2016) using MeSH terms proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole, and muscular diseases Additionally, a search was conducted in ToxNet and EMBASE using similar search criteria...
August 18, 2016: Annals of Pharmacotherapy
Barbara Farrell, Kevin Pottie, Carlos H Rojas-Fernandez, Lise M Bjerre, Wade Thompson, Vivian Welch
BACKGROUND: Class specific deprescribing guidelines could help clinicians taper and stop medications no longer needed or which may be causing more harm than benefit. We set out to develop methodology to create such guidelines using evidence-based methods for guideline development, evidence synthesis and recommendation rating. METHODS AND FINDINGS: Using a comprehensive checklist for a successful guideline enterprise, we conducted a national modified Delphi consensus process to identify priorities for deprescribing guidelines, then conducted scoping exercises to identify feasible topics, and sequentially developed three deprescribing guidelines...
2016: PloS One
Luis A García Rodríguez, Mar Martín-Pérez, Charles H Hennekens, Peter M Rothwell, Angel Lanas
BACKGROUND: Low-dose aspirin has proven effectiveness in secondary and primary prevention of cardiovascular events, but is also associated with an increased risk of major bleeding events. For primary prevention, this absolute risk must be carefully weighed against the benefits of aspirin; such assessments are currently limited by a lack of data from general populations. METHODS: Systematic searches of Medline and Embase were conducted to identify observational studies published between 1946 and 4 March 2015 that reported the risks of gastrointestinal (GI) bleeding or intracranial hemorrhage (ICH) with long-term, low-dose aspirin (75-325 mg/day)...
2016: PloS One
Yoomi Lee, Aleksandra M Urbanska, Yoku Hayakawa, Hongshan Wang, Andrew S Au, Aesis M Luna, Wenju Chang, Guangchun Jin, Govind Bhagat, Julian A Abrams, Richard A Friedman, Andrea Varro, Kenneth K Wang, Malcolm Boyce, Anil K Rustgi, Antonia R Sepulveda, Michael Quante, Timothy C Wang
OBJECTIVE: The incidence of esophageal adenocarcinoma (EAC) is increasing, but factors contributing to malignant progression of its precursor lesion, Barrett's esophagus (BE), have not been defined. Hypergastrinemia caused by long-term use of proton pump inhibitors (PPIs), has been suggested as one possible risk factor. The gastrin receptor, CCK2R, is expressed in the cardia and upregulated in BE, suggesting the involvement of the gastrin-CCK2R pathway in progression. In the L2-IL-1β mouse model, Barrett's-like esophagus arises from the gastric cardia...
July 18, 2016: Oncotarget
E Balza, P Piccioli, S Carta, R Lavieri, M Gattorno, C Semino, P Castellani, A Rubartelli
Incidence of sepsis is increasing, representing a tremendous burden for health-care systems. Death in acute sepsis is attributed to hyperinflammatory responses, but the underlying mechanisms are still unclear. We report here that proton pump inhibitors (PPIs), which block gastric acid secretion, selectively inhibited tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) secretion by Toll-like receptor (TLR)-activated human monocytes in vitro, in the absence of toxic effects. Remarkably, the oversecretion of IL-1β that represents a hallmark of monocytes from patients affected by cryopyrin-associated periodic syndrome is also blocked...
2016: Cell Death & Disease
Thurid Ahlenstiel-Grunow, Nele K Kanzelmeyer, Kerstin Froede, Martin Kreuzer, Jens Drube, Christian Lerch, Lars Pape
BACKGROUND: Nephropathic cystinosis is a rare lysosomal storage disease which is characterized by the accumulation of free cystine in lysosomes and subsequent intracellular crystal formation of cystine throughout the body. If not treated with cysteamine, a cystine-depleting agent, end-stage renal disease will develop early, followed by multiple organ failure as the disease progresses. The established cysteamine formulation requires a strict dosing regimen at 6-h intervals. An extended release (ER) twice-daily formulation has recently been developed...
June 27, 2016: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
N J de Wit, M E Numans
Large population studies published recently have revealed additional risks of chronic use of proton pump inhibitors (PPIs). Dementia and renal failure were reported as long-term follow-up side effects of chronic use, in addition to the previously known increased risk for various infections, osteoporosis and metabolic disturbances. In the light of ongoing over-prescription of PPIs, this should lead to reconsideration of individual indications.
2016: Nederlands Tijdschrift Voor Geneeskunde
Kristin M Aasarød, Masoud Ramezanzadehkoldeh, Maziar Shabestari, Mats P Mosti, Astrid K Stunes, Janne E Reseland, Vidar Beisvag, Erik Fink Eriksen, Arne K Sandvik, Reinhold G Erben, Christiane Schüler, Malcolm Boyce, Bjørn H Skallerud, Unni Syversen, Reidar Fossmark
Epidemiological studies suggest an increased fracture risk in patients taking proton pump inhibitors (PPIs) for long term. The underlying mechanism, however, has been disputed. By binding to the gastric proton pump, PPIs inhibit gastric acid secretion. We have previously shown that proton pump (H(+)/K(+)ATPase beta subunit) KO mice exhibit reduced bone mineral density (BMD) and inferior bone strength compared with WT mice. Patients using PPIs as well as these KO mice exhibit gastric hypoacidity, and subsequently increased serum concentrations of the hormone gastrin...
August 2016: Journal of Endocrinology
Wade Thompson, Matthew Hogel, Yan Li, Kednapa Thavorn, Denis O'Donnell, Lisa McCarthy, Lisa Dolovich, Cody Black, Barbara Farrell
OBJECTIVES: To assess the effect of a proton pump inhibitor (PPI) deprescribing guideline on PPI usage and PPI drug costs in one long-term care home in Ontario, Canada. DESIGN: Interrupted time-series analysis to compare monthly PPI usage and average monthly PPI cost per resident 9 months before guideline implementation to 12 months after. SETTING: One long-term care home in Ottawa, Ontario, Canada. PARTICIPANTS: Long-term care residents prescribed a PPI over a 21-month period (n = 335)...
July 1, 2016: Journal of the American Medical Directors Association
Fatmah Othman, Timothy R Card, Colin J Crooks
PURPOSE: To determine the prevalence and pattern of proton pump inhibitor (PPI) prescription and the practices employed to reduce PPI use in the UK general population. METHODS: The UK's Clinical Practice Research Database was used to identify individuals who were issued with ≥1 PPI prescription during the period 1990-2014. Point and period prevalence of PPI use were estimated annually. Additionally, new users of PPI therapy who had 5 years of follow-up data were included in a cohort analysis to describe patterns of cessation and duration of PPI use...
September 2016: Pharmacoepidemiology and Drug Safety
Rena K Fox, Thiruvengadam Muniraj
Several key areas in gastroenterology pharmacotherapy are rapidly evolving, including the treatment of hepatitis C virus (HCV), irritable bowel syndrome, gastroesophageal reflux disease (GERD) and peptic ulcer disease. HCV treatment has radically changed in the past 2 years and now most patients are treatment candidates and have a high likelihood of permanent cure. Pharmacotherapy is now first-line treatment for patients with moderate to severe symptoms of irritable bowel syndrome. Proton pump inhibitors (PPIs) are the mainstay of therapy in gastric and duodenal ulcers and GERD, although long-term use carries the risk of several side effects that should be considered...
July 2016: Medical Clinics of North America
Bjarne Nesgaard Andersen, Per Birger Johansen, Bo Abrahamsen
PURPOSE OF REVIEW: The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and how this has influenced our understanding of this association, the clinical impact and the underlying pathophysiology. RECENT FINDINGS: New studies have further strengthened existing evidence linking use of PPIs to osteoporosis...
July 2016: Current Opinion in Rheumatology
An Tran-Duy, Bart Spaetgens, Arno W Hoes, Niek J de Wit, Coen D A Stehouwer
BACKGROUND & AIMS: There have been increasing numbers of case reports and observational studies of adverse events in patients receiving long-term therapy with proton pump inhibitors (PPIs). The effects of PPI therapy on risks of fundic gland polyps (FGPs) and gastric cancer have received considerable attention. We performed a systematic review with a meta-analysis of randomized controlled trials and observational studies that assessed these risks. METHODS: We searched the PUBMED, EMBASE, and Cochrane Central Register of Controlled Trials databases for relevant studies published through July 2015...
May 20, 2016: Clinical Gastroenterology and Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"